Novamind looks to scale mental health clinics and clinical sites with shift in psychedelics policies

Novamind Inc. (CSE:NM) CEO Yaron Conforti tells Proactive the Toronto-based group is looking to scale its mental health clinics and its clinical research sites as policy around psychedelic drugs shifts in the US and around the world. Conforti says part of the group's plan when it chose to go public, was to expand its reach into the US. The group currently has mental health clinics in various locations in Utah, and offers its clients access to ketamine therapies.